Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...
Fierce Pharma6d
In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ
A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, ...
Halozyme Therapeutics’ (HALO) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report published on Thursday,Benzinga reports. Several other equities analysts have also ...
Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...
BioSpace7d
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...
New version of Merck's cancer drug faces possible patent battle: reports
Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.